Robert H. Pass
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert H. Pass has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Lynn Nappo
The Children's Hospital at Montefiore, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA
6 shared publicationsLeonardo Liberman
New York Presbyterian Hospital, Children's Hospital of NY, Columbia University College of Physicians and Surgeons, New York, NY, USA
5 shared publications- Leonardo Liberman
Department of Pediatric Cardiology, Columbia University Irving Medical Center
4 shared publications Scott R. Ceresnak
Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, USA
4 shared publicationsWilliam E. Hellenbrand
4 shared publicationsAllan J Hordof
Pediatric Arrhythmia Service, Division of Pediatric Cardiology, Children’s Hospital of New York New York, New York USA
3 shared publications
Latest Publications
- 12 January 2018
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 41 (4) , 368-371
The “hidden” concealed left‐sided accessory pathway: An uncommon cause of SVT in young people
Background: Concealed left‐sided accessory pathways (CLAP) are a cause of supraventricular tachycardia (SVT) in the young. Most are mapped with right ventricular (RV) apical/outflow pacing. Rarely, alternative means of mapping are required. We review our experience from three pediatric electrophysiology (EP) centers with a rare form of “hidden” CLAP.Methods: All patients <21 years undergoing EP study from 2008 to 2014 with a “hidden” CLAP (defined as an accessory pathway [AP] for which RV pacing at cycle lengths [CL] stable for mapping did not demonstrate eccentric retrograde conduction) were included. Exclusion criteria: preexcitation. Demographic, procedural, and follow‐up data were collected.Results: A total of 23 patients met the criteria (median age, 14.3 years [range 7–21], weight, 51 kg [31–99]). 21 (96%) had SVT and one AFIB (4%). APs were adenosine sensitive in 7/20 patients (35%) and VA conduction was decremental in six (26%). CLAP conduction was demonstrable with orthodromic reentrant tachycardia in all patients, with RV extrastimulus testing in seven (30%) and with rapid RV pacing (<CL 300) in three (13%). Left ventricular (LV) pacing demonstrated CLAP conduction in 17/17 (100%) patients in whom it was used. All 23 CLAPs were successfully ablated (100%) via transseptal approach with radiofrequency energy. Specific ablation techniques included: 16 (70%) during LV paced rhythm, four (17%) during orthodromic reciprocating tachycardia (ORT; 3/4 ventricular entrained), and three (13%) with brief rapid RV pacing. There were no complications. At 18 months (range 3–96), there was one recurrence (4%).Conclusions: Some CLAPs are only demonstrable with LV pacing, entrained ORT, or rapid RV pacing. LV pacing facilitated preferential AP conduction, allowing for mapping while maintaining stable hemodynamics.
- 12 January 2018
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 41 (4) , 368-371
The “hidden” concealed left‐sided accessory pathway: An uncommon cause of SVT in young people
Background: Concealed left‐sided accessory pathways (CLAP) are a cause of supraventricular tachycardia (SVT) in the young. Most are mapped with right ventricular (RV) apical/outflow pacing. Rarely, alternative means of mapping are required. We review our experience from three pediatric electrophysiology (EP) centers with a rare form of “hidden” CLAP.Methods: All patients <21 years undergoing EP study from 2008 to 2014 with a “hidden” CLAP (defined as an accessory pathway [AP] for which RV pacing at cycle lengths [CL] stable for mapping did not demonstrate eccentric retrograde conduction) were included. Exclusion criteria: preexcitation. Demographic, procedural, and follow‐up data were collected.Results: A total of 23 patients met the criteria (median age, 14.3 years [range 7–21], weight, 51 kg [31–99]). 21 (96%) had SVT and one AFIB (4%). APs were adenosine sensitive in 7/20 patients (35%) and VA conduction was decremental in six (26%). CLAP conduction was demonstrable with orthodromic reentrant tachycardia in all patients, with RV extrastimulus testing in seven (30%) and with rapid RV pacing (<CL 300) in three (13%). Left ventricular (LV) pacing demonstrated CLAP conduction in 17/17 (100%) patients in whom it was used. All 23 CLAPs were successfully ablated (100%) via transseptal approach with radiofrequency energy. Specific ablation techniques included: 16 (70%) during LV paced rhythm, four (17%) during orthodromic reciprocating tachycardia (ORT; 3/4 ventricular entrained), and three (13%) with brief rapid RV pacing. There were no complications. At 18 months (range 3–96), there was one recurrence (4%).Conclusions: Some CLAPs are only demonstrable with LV pacing, entrained ORT, or rapid RV pacing. LV pacing facilitated preferential AP conduction, allowing for mapping while maintaining stable hemodynamics.
- 25 October 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 92 (5) , 1009-1010
Letter to the editor regarding Cevallos PC et al. Radiation dose benchmarks in pediatric cardiac catheterization: A prospective multi-center C3P0-QI study. Catheter Cardiovasc Interv. 2017 Aug;90(2):269-280
- 25 October 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 92 (5) , 1009-1010
Letter to the editor regarding Cevallos PC et al. Radiation dose benchmarks in pediatric cardiac catheterization: A prospective multi-center C3P0-QI study. Catheter Cardiovasc Interv. 2017 Aug;90(2):269-280
- 30 June 2017
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 40 (7) , 798-802
A multicenter review of ablation in the aortic cusps in young people
Background: Ablation within the aortic cusp is safe and effective in adults. There are little data on aortic cusp ablation in the pediatric literature. We investigated the safety and efficacy of aortic cusp ablation in young patients.Methods: A retrospective, descriptive study of aortic cusp ablation in five pediatric electrophysiology centers from 2008 to 2014 was performed. All patients 2 [range 1.12–2.33]). Substrates for ablation included: nine premature ventricular contractions or sustained ventricular tachycardia (69%), two concealed anteroseptal accessory pathways (APs) (15%), one Wolff‐Parkinson‐White with an anteroseptal AP (8%), and one ectopic atrial tachycardia (8%). Three‐dimensional electroanatomic mapping in combination with fluoroscopy was used in 12/13 (92%) patients. Standard 4‐mm‐tip radiofrequency (RF) current was used in 11/13 (85%) and low‐power irrigated‐tip RF in 2/13 (15%). Angiography was used in 13/13 and intracardiac echocardiography was additionally utilized in 3/13 (23%). Ablation locations included: eight noncoronary (62%), three left (23%), and two right (15%) cusps. Ablation was acutely successful in all patients. At median follow‐up of 20 months, there was one recurrence of PVCs (8%). There were no ablation‐related complications and no valvular injuries observed.Conclusion: Arrhythmias originating from the coronary cusps in this series were successfully and safely ablated in young people without injury to the coronary arteries or the aortic valve.
- 30 June 2017
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 40 (7) , 798-802
A multicenter review of ablation in the aortic cusps in young people
Background: Ablation within the aortic cusp is safe and effective in adults. There are little data on aortic cusp ablation in the pediatric literature. We investigated the safety and efficacy of aortic cusp ablation in young patients.Methods: A retrospective, descriptive study of aortic cusp ablation in five pediatric electrophysiology centers from 2008 to 2014 was performed. All patients 2 [range 1.12–2.33]). Substrates for ablation included: nine premature ventricular contractions or sustained ventricular tachycardia (69%), two concealed anteroseptal accessory pathways (APs) (15%), one Wolff‐Parkinson‐White with an anteroseptal AP (8%), and one ectopic atrial tachycardia (8%). Three‐dimensional electroanatomic mapping in combination with fluoroscopy was used in 12/13 (92%) patients. Standard 4‐mm‐tip radiofrequency (RF) current was used in 11/13 (85%) and low‐power irrigated‐tip RF in 2/13 (15%). Angiography was used in 13/13 and intracardiac echocardiography was additionally utilized in 3/13 (23%). Ablation locations included: eight noncoronary (62%), three left (23%), and two right (15%) cusps. Ablation was acutely successful in all patients. At median follow‐up of 20 months, there was one recurrence of PVCs (8%). There were no ablation‐related complications and no valvular injuries observed.Conclusion: Arrhythmias originating from the coronary cusps in this series were successfully and safely ablated in young people without injury to the coronary arteries or the aortic valve.
- Open Access
- 28 June 2016
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 175 (9) , 1235-1248
Congenital and childhood atrioventricular blocks: pathophysiology and contemporary management
Atrioventricular block is classified as congenital if diagnosed in utero, at birth, or within the first month of life. The pathophysiological process is believed to be due to immune-mediated injury of the conduction system, which occurs as a result of transplacental passage of maternal anti-SSA/Ro-SSB/La antibodies. Childhood atrioventricular block is therefore diagnosed between the first month and the 18th year of life. Genetic variants in multiple genes have been described to date in the pathogenesis of inherited progressive cardiac conduction disorders. Indications and techniques of cardiac pacing have also evolved to allow safe permanent cardiac pacing in almost all patients, including those with structural heart abnormalities. Conclusion: Early diagnosis and appropriate management are critical in many cases in order to prevent sudden death, and this review critically assesses our current understanding of the pathogenetic mechanisms, clinical course, and optimal management of congenital and childhood AV block. What is Known: • Prevalence of congenital heart block of 1 per 15,000 to 20,000 live births. AV block is defined as congenital if diagnosed in utero, at birth, or within the first month of life, whereas childhood AV block is diagnosed between the first month and the 18th year of life. As a result of several different etiologies, congenital and childhood atrioventricular block may occur in an entirely structurally normal heart or in association with concomitant congenital heart disease. Cardiac pacing is indicated in symptomatic patients and has several prophylactic indications in asymptomatic patients to prevent sudden death. • Autoimmune, congenital AV block is associated with a high neonatal mortality rate and development of dilated cardiomyopathy in 5 to 30 % cases. What is New: • Several genes including SCN5A have been implicated in autosomal dominant forms of familial progressive cardiac conduction disorders. • Leadless pacemaker technology and gene therapy for biological pacing are promising research fields. In utero percutaneous pacing appears to be at high risk and needs further development before it can be adopted into routine clinical practice. Cardiac resynchronization therapy is of proven value in case of pacing-induced cardiomyopathy.
- 28 June 2016
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 175 (9) , 1235-1248
Open AccessCongenital and childhood atrioventricular blocks: pathophysiology and contemporary management
Atrioventricular block is classified as congenital if diagnosed in utero, at birth, or within the first month of life. The pathophysiological process is believed to be due to immune-mediated injury of the conduction system, which occurs as a result of transplacental passage of maternal anti-SSA/Ro-SSB/La antibodies. Childhood atrioventricular block is therefore diagnosed between the first month and the 18th year of life. Genetic variants in multiple genes have been described to date in the pathogenesis of inherited progressive cardiac conduction disorders. Indications and techniques of cardiac pacing have also evolved to allow safe permanent cardiac pacing in almost all patients, including those with structural heart abnormalities. Conclusion: Early diagnosis and appropriate management are critical in many cases in order to prevent sudden death, and this review critically assesses our current understanding of the pathogenetic mechanisms, clinical course, and optimal management of congenital and childhood AV block. What is Known: • Prevalence of congenital heart block of 1 per 15,000 to 20,000 live births. AV block is defined as congenital if diagnosed in utero, at birth, or within the first month of life, whereas childhood AV block is diagnosed between the first month and the 18th year of life. As a result of several different etiologies, congenital and childhood atrioventricular block may occur in an entirely structurally normal heart or in association with concomitant congenital heart disease. Cardiac pacing is indicated in symptomatic patients and has several prophylactic indications in asymptomatic patients to prevent sudden death. • Autoimmune, congenital AV block is associated with a high neonatal mortality rate and development of dilated cardiomyopathy in 5 to 30 % cases. What is New: • Several genes including SCN5A have been implicated in autosomal dominant forms of familial progressive cardiac conduction disorders. • Leadless pacemaker technology and gene therapy for biological pacing are promising research fields. In utero percutaneous pacing appears to be at high risk and needs further development before it can be adopted into routine clinical practice. Cardiac resynchronization therapy is of proven value in case of pacing-induced cardiomyopathy.
- 22 August 2014
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 25 (5) , 963-968
Reducing patient radiation exposure during paediatric SVT ablations: use of CARTO® 3 in concert with “ALARA” principles profoundly lowers total dose
Background: “ALARA – As Low As Reasonably Achievable” protocols reduce patient radiation dose. Addition of electroanatomical mapping may further reduce dose. Methods: From 6/11 to 4/12, a novel ALARA protocol was utilised for all patients undergoing supraventricular tachycardia ablation, including low frame rates (2–3 frames/second), low fluoro dose/frame (6–18 nGy/frame), and other techniques to reduce fluoroscopy (ALARA). From 6/12 to 3/13, use of CARTO® 3 (C3) with “fast anatomical mapping” (ALARA+C3) was added to the ALARA protocol. Intravascular echo was not utilised. Demographics, procedural, and radiation data were analysed and compared between the two protocols. Results: A total of 75 patients were included: 42 ALARA patients, and 33 ALARA+C3 patients. Patient demographics were similar between the two groups. The acute success rate in ALARA was 95%, and 100% in ALARA+C3; no catheterisation-related complications were observed. Procedural time was 125.7 minutes in the ALARA group versus 131.4 in ALARA+C3 (p=0.36). Radiation doses were significantly lower in the ALARA+C3 group with a mean air Kerma in ALARA+C3 of 13.1±28.3 mGy (SD) compared with 93.8±112 mGy in ALARA (pConclusions: Addition of CARTO® 3 to ALARA protocols markedly reduced radiation exposure to young people undergoing supraventricular tachycardia ablation while allowing for equivalent procedural efficacy and safety.
- 22 August 2014
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 25 (5) , 963-968
Reducing patient radiation exposure during paediatric SVT ablations: use of CARTO® 3 in concert with “ALARA” principles profoundly lowers total dose
Background: “ALARA – As Low As Reasonably Achievable” protocols reduce patient radiation dose. Addition of electroanatomical mapping may further reduce dose. Methods: From 6/11 to 4/12, a novel ALARA protocol was utilised for all patients undergoing supraventricular tachycardia ablation, including low frame rates (2–3 frames/second), low fluoro dose/frame (6–18 nGy/frame), and other techniques to reduce fluoroscopy (ALARA). From 6/12 to 3/13, use of CARTO® 3 (C3) with “fast anatomical mapping” (ALARA+C3) was added to the ALARA protocol. Intravascular echo was not utilised. Demographics, procedural, and radiation data were analysed and compared between the two protocols. Results: A total of 75 patients were included: 42 ALARA patients, and 33 ALARA+C3 patients. Patient demographics were similar between the two groups. The acute success rate in ALARA was 95%, and 100% in ALARA+C3; no catheterisation-related complications were observed. Procedural time was 125.7 minutes in the ALARA group versus 131.4 in ALARA+C3 (p=0.36). Radiation doses were significantly lower in the ALARA+C3 group with a mean air Kerma in ALARA+C3 of 13.1±28.3 mGy (SD) compared with 93.8±112 mGy in ALARA (pConclusions: Addition of CARTO® 3 to ALARA protocols markedly reduced radiation exposure to young people undergoing supraventricular tachycardia ablation while allowing for equivalent procedural efficacy and safety.
- 25 March 2014
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 37 (8) , 1051-1057
Effects of Ventilation and Catheter Position on Catheter Movement on the Tricuspid Annulus during Ablation in Children
There are little data on the effect of catheter position and mechanical ventilation on ablation catheter stability during electrophysiology study in children. We sought to determine the magnitude of catheter movement with mechanical ventilation, the effect of ventilation maneuvers on catheter movement, and to compare the degree of movement observed between the right lateral (RL) and right posteroseptal (RPS) regions. From June 2012 to June 2013, patients ≤ 21 years of age undergoing ablation for supraventricular tachycardia with CARTO® 3 (Biosense Webster, Diamond Bar, CA, USA) were included. During mapping the ablation catheter was placed in the RPS and RL regions and the magnitude of catheter movement (mm) was measured using CARTO® 3. Measurements were made during routine ventilation and with a maximal inspiration maneuver between end-expiration (ENDEX) and peak-inspiration (PEAKINS). Twenty-one patients were included: 12 males (57%), age 13 ± 3 years, weight 55 ± 14 kg. Indications for ablation were: 10 Wolff-Parkinson-White, seven atrioventricular node re-entry tachycardia, four concealed accessory pathway. Mechanical ventilation was used in all cases. The magnitude of catheter movement was 3.6 ± 1.7 mm with routine ventilation and 6.2 ± 4.1 mm between ENDEX and PEAKINS (P ≤ 0.01). Catheter movement was greater in the RL compared to the RPS region with routine ventilation (RL 4.3 ± 1.6 vs RPS 3.0 ± 1.5; P < 0.01) and between ENDEX and PEAKINS (RL 8.3 ± 4.7 vs RPS 4.0 ± 1.7; P < 0.01). Ventilation and catheter position both have significant impact on the degree of catheter movement during ablation. Movement was greatest in the RL position. This may partially explain the lower success rates of ablation in the RL region.
- 25 March 2014
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 37 (8) , 1051-1057
Effects of Ventilation and Catheter Position on Catheter Movement on the Tricuspid Annulus during Ablation in Children
There are little data on the effect of catheter position and mechanical ventilation on ablation catheter stability during electrophysiology study in children. We sought to determine the magnitude of catheter movement with mechanical ventilation, the effect of ventilation maneuvers on catheter movement, and to compare the degree of movement observed between the right lateral (RL) and right posteroseptal (RPS) regions. From June 2012 to June 2013, patients ≤ 21 years of age undergoing ablation for supraventricular tachycardia with CARTO® 3 (Biosense Webster, Diamond Bar, CA, USA) were included. During mapping the ablation catheter was placed in the RPS and RL regions and the magnitude of catheter movement (mm) was measured using CARTO® 3. Measurements were made during routine ventilation and with a maximal inspiration maneuver between end-expiration (ENDEX) and peak-inspiration (PEAKINS). Twenty-one patients were included: 12 males (57%), age 13 ± 3 years, weight 55 ± 14 kg. Indications for ablation were: 10 Wolff-Parkinson-White, seven atrioventricular node re-entry tachycardia, four concealed accessory pathway. Mechanical ventilation was used in all cases. The magnitude of catheter movement was 3.6 ± 1.7 mm with routine ventilation and 6.2 ± 4.1 mm between ENDEX and PEAKINS (P ≤ 0.01). Catheter movement was greater in the RL compared to the RPS region with routine ventilation (RL 4.3 ± 1.6 vs RPS 3.0 ± 1.5; P < 0.01) and between ENDEX and PEAKINS (RL 8.3 ± 4.7 vs RPS 4.0 ± 1.7; P < 0.01). Ventilation and catheter position both have significant impact on the degree of catheter movement during ablation. Movement was greatest in the RL position. This may partially explain the lower success rates of ablation in the RL region.
- 18 November 2013
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 83 (4) , 591-594
Intervening for RPA stenosis following Waterston shunt: Importance of anatomical definition of the coronary arteries
- 18 November 2013
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 83 (4) , 591-594
Intervening for RPA stenosis following Waterston shunt: Importance of anatomical definition of the coronary arteries
- 1 October 2013
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 58 (4) , 1161
Hemoptysis and Thoracic Aneurysm 40 Years Following Subclavian-Aortic Bypass for Coarctation Treated With Endograft and Amplatzer Plug
- 1 October 2013
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 58 (4) , 1161
Hemoptysis and Thoracic Aneurysm 40 Years Following Subclavian-Aortic Bypass for Coarctation Treated With Endograft and Amplatzer Plug
- 19 March 2013
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 36 (6) , 688-694
Reducing Patient Radiation Dosage during Pediatric SVT Ablations Using an “ALARA” Radiation Reduction Protocol in the Modern Fluoroscopic Era
Background: Ablation for supraventricular tachycardia (SVT) relies upon fluoroscopy (fluoro), which exposes the patient and staff to ionizing radiation. The objective of this work was to present a new “ALARA—As Low As Reasonably Achievable” protocol with alterations to fluoroscopic x‐ray parameters to reduce dose without an electroanatomical (EAM) approach.Methods: All patients 2 (range 0.72– 1.94 m2). Seventeen (41%) had Wolff‐Parkinson‐White syndrome, 14 (33%) atrioventricular nodal reentrant tachycardia, and 11 (26%) concealed pathways. Median procedural time was 114 minutes (57–246 minutes). Median dose area product (DAP) for posterioanterior and lateral fluoroscopy was 343.2 uGym2 (range 38.2–3,172 uGym2); the median air Kerma product (K) was 45.4 mGy (range 6.7–567.5 mGy). DAP and K are lower than prior data from EAM and fluoroscopy techniques. The acute success rate was 95%; no procedural complications.Conclusions: An ALARA protocol for ablation of SVT reduced radiation to below levels previously reported for combined EAM/fluoro approaches. Success rates were excellent with no complications and without the costs of EAM.
- 19 March 2013
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 36 (6) , 688-694
Reducing Patient Radiation Dosage during Pediatric SVT Ablations Using an “ALARA” Radiation Reduction Protocol in the Modern Fluoroscopic Era
Background: Ablation for supraventricular tachycardia (SVT) relies upon fluoroscopy (fluoro), which exposes the patient and staff to ionizing radiation. The objective of this work was to present a new “ALARA—As Low As Reasonably Achievable” protocol with alterations to fluoroscopic x‐ray parameters to reduce dose without an electroanatomical (EAM) approach.Methods: All patients 2 (range 0.72– 1.94 m2). Seventeen (41%) had Wolff‐Parkinson‐White syndrome, 14 (33%) atrioventricular nodal reentrant tachycardia, and 11 (26%) concealed pathways. Median procedural time was 114 minutes (57–246 minutes). Median dose area product (DAP) for posterioanterior and lateral fluoroscopy was 343.2 uGym2 (range 38.2–3,172 uGym2); the median air Kerma product (K) was 45.4 mGy (range 6.7–567.5 mGy). DAP and K are lower than prior data from EAM and fluoroscopy techniques. The acute success rate was 95%; no procedural complications.Conclusions: An ALARA protocol for ablation of SVT reduced radiation to below levels previously reported for combined EAM/fluoro approaches. Success rates were excellent with no complications and without the costs of EAM.
- 16 March 2012
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 80 (2) , 177-181
A new “tool” for transcatheter atrial defect closure: The St. Jude SL2™ sheath
Background: Orienting the left atrial disc of an atrial septal defect (ASD) closure device parallel to the septum is important, particularly in cases of ASD with deficient retroaortic rim. Standard vascular sheaths can make this challenging. We report the use of an electrophysiologic sheath, the SL2™ St. Jude Vascular sheath (St. Jude Medical, St. Paul, MN) for closure of ASD.Methods: All patients undergoing ASD closure between July 2010 and February 2011 at The Children's Hospital at Montefiore in which the SL2 sheath was used were reviewed.Results: Nine patients underwent transcatheter ASD or PFO (1/9) closure with the SL2 sheath. Mean age was 22.7 years (range, 3–58); weight was 46.5 kg (range, 14.7–78.6). The Amplatzer ASD Occluder (AGA Medical Corp., Plymouth, MN) was used in all cases. The mean measurement of the ASDs via “stop‐flow” technique was 13.3 mm (range, 4–19). The mean device size was 13.9 mm (range, 5–20) or 105% the size of the defect. The retroaortic rim was deficient (<2 mm) in 3 of 9. ASD closure was achieved in 9 of 9. In all, the left atrial disk was brought toward the atrial septum parallel to the atrial septum, and repositioning or recapturing of the device was unnecessary in any case. Mean fluoroscopy time was 9.3 min (range, 2.2–18). No significant complications.Conclusions: The SL2 sheath was useful to position the ASD device parallel to the atrial septum, eliminating the need for redeployment during the procedure. This sheath was useful in those cases of deficient retroaortic rim in this study.
- 16 March 2012
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 80 (2) , 177-181
A new “tool” for transcatheter atrial defect closure: The St. Jude SL2™ sheath
Background: Orienting the left atrial disc of an atrial septal defect (ASD) closure device parallel to the septum is important, particularly in cases of ASD with deficient retroaortic rim. Standard vascular sheaths can make this challenging. We report the use of an electrophysiologic sheath, the SL2™ St. Jude Vascular sheath (St. Jude Medical, St. Paul, MN) for closure of ASD.Methods: All patients undergoing ASD closure between July 2010 and February 2011 at The Children's Hospital at Montefiore in which the SL2 sheath was used were reviewed.Results: Nine patients underwent transcatheter ASD or PFO (1/9) closure with the SL2 sheath. Mean age was 22.7 years (range, 3–58); weight was 46.5 kg (range, 14.7–78.6). The Amplatzer ASD Occluder (AGA Medical Corp., Plymouth, MN) was used in all cases. The mean measurement of the ASDs via “stop‐flow” technique was 13.3 mm (range, 4–19). The mean device size was 13.9 mm (range, 5–20) or 105% the size of the defect. The retroaortic rim was deficient (<2 mm) in 3 of 9. ASD closure was achieved in 9 of 9. In all, the left atrial disk was brought toward the atrial septum parallel to the atrial septum, and repositioning or recapturing of the device was unnecessary in any case. Mean fluoroscopy time was 9.3 min (range, 2.2–18). No significant complications.Conclusions: The SL2 sheath was useful to position the ASD device parallel to the atrial septum, eliminating the need for redeployment during the procedure. This sheath was useful in those cases of deficient retroaortic rim in this study.